Hirsch Sandra, Pia De la Maza M, Yañez Paulina, Glasinovic Andrea, Petermann Margarita, Barrera Gladys, Gattas Vivian, Escobar Edgardo, Bunout Daniel
Institute of Nutrition and Food Technology, University of Chile, Santiago.
Clin Cardiol. 2002 Nov;25(11):495-501. doi: 10.1002/clc.4960251105.
The relationship between hyperhomocysteinemia and cardiovascular disease has not been totally elucidated.
The study aimed to verify the association between hyperhomocysteinemia and endothelial dysfunction before and after modification of total homocysteine (tHcy) serum levels with vitamin supplementation in young male subjects devoid of any other cardiovascular risk factor.
Twenty hyperhomocysteinemic (tHcy > 15 [micromol/l) male volunteers (< or = 40 years) and 20 age-matched subjects with normal tHcy levels (tHcy < 13 micromol/l) were included. Exclusion criteria were smoking, hypertension, diabetes, vitamin ingestion, obesity, hypercholesterolemia, renal failure, and positive antiphospholipid antibodies. Serum tHcy, folate, vitamin B12 levels, activated protein C and S, protein C resistance, fibrinogen, prothrombin, thrombin, antithrombin III, and in vitro oxidation of low-density lipoprotein (LDL) particles were measured. Noninvasive ultrasound measurements of endothelium-dependent (EDD) and -independent dilatation (EID) of the brachial artery were performed. Each pair was then randomly assigned to receive a vitamin capsule (0.6 mg folic acid, 0.8 mg B12. and 2.0 mg B6) oran identical placebo during 8 weeks, in a double-blind study design. After the treatment phase, blood samples and vascular reactivity were repeated.
Nine pairs of volunteers received vitamins and 11 received placebo. Hyperhomocysteinemic subjects had lower baseline serum levels of vitamin B12. Serum folate levels, antithrombotic function, in vitro LDL oxidation, and EDD were similar in all groups. After the vitamin supplementation, serum folic acid levels increased significantly both in normo- and hyperhomocysteinemic subjects, unlike vitamin B12, which increased only in the hyperhomocysteinemic individuals. Plasma tHcy decreased significantly in the supplemented groups. Treatment with vitamins was not associated with improvement in EDD or antithrombotic function.
Mild hyperhomocysteinemia is not associated with endothelial dysfunction in young male subjects with no additional cardiovascular risk factors, and reduction of tHcy by vitamin supplementation does not modify EDD in this age group. In this sample, tHcy was more related to vitamin B12 than to folic acid status.
高同型半胱氨酸血症与心血管疾病之间的关系尚未完全阐明。
本研究旨在验证在无其他心血管危险因素的年轻男性受试者中,补充维生素使血清总同型半胱氨酸(tHcy)水平改变前后,高同型半胱氨酸血症与内皮功能障碍之间的关联。
纳入20名高同型半胱氨酸血症(tHcy>15[微摩尔/升])男性志愿者(≤40岁)和20名年龄匹配的tHcy水平正常(tHcy<13微摩尔/升)的受试者。排除标准包括吸烟、高血压、糖尿病、维生素摄入、肥胖、高胆固醇血症、肾衰竭和抗磷脂抗体阳性。检测血清tHcy、叶酸、维生素B12水平、活化蛋白C和S、蛋白C抵抗、纤维蛋白原、凝血酶原、凝血酶、抗凝血酶III以及低密度脂蛋白(LDL)颗粒的体外氧化情况。采用无创超声测量肱动脉的内皮依赖性舒张(EDD)和非内皮依赖性舒张(EID)。然后,在一项双盲研究设计中,将每对受试者随机分配接受维生素胶囊(0.6毫克叶酸、0.8毫克维生素B12和2.0毫克维生素B6)或相同的安慰剂,持续8周。治疗阶段结束后,重复采集血样并检测血管反应性。
9对志愿者接受了维生素治疗,11对接受了安慰剂治疗。高同型半胱氨酸血症受试者的维生素B12基线血清水平较低。所有组的血清叶酸水平、抗血栓形成功能、体外LDL氧化和EDD相似。补充维生素后,正常同型半胱氨酸血症和高同型半胱氨酸血症受试者的血清叶酸水平均显著升高,而维生素B12仅在高同型半胱氨酸血症个体中升高。补充组的血浆tHcy显著降低。维生素治疗与EDD或抗血栓形成功能的改善无关。
在无其他心血管危险因素的年轻男性受试者中,轻度高同型半胱氨酸血症与内皮功能障碍无关,补充维生素降低tHcy并不能改善该年龄组的EDD。在本样本中,tHcy与维生素B12的关系比与叶酸状态的关系更为密切。